Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Survivin and Fas Ligand Expressions Are Correlated with Angiolymphatic Tumor Spread in Medullary Thyroid Carcinoma

´ëÇѺ´¸®ÇÐȸÁö 2005³â 39±Ç 5È£ p.320 ~ 325
±è¹Î°æ, ¹Ú¼ºÇý, ÁÖ¹Ì, ¼ÕÁøÈñ, ä½Â¿Ï, ¹Ú¼ºÈ£, ±èÇѼº, ±è¾îÁø,
¼Ò¼Ó »ó¼¼Á¤º¸
±è¹Î°æ ( Kim Min-Kyoung ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °­ºÏ»ï¼ºº´¿ø º´¸®°úÇб³½Ç

¹Ú¼ºÇý ( Park Sung-Hye ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
Áֹ̠( Joo Mee ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ÀÏ»ê¹éº´¿ø º´¸®°ú
¼ÕÁøÈñ ( Sohn Jin-Hee ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °­ºÏ»ï¼ºº´¿ø º´¸®°úÇб³½Ç
ä½Â¿Ï ( Chae Seoung-Wan ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °­ºÏ»ï¼ºº´¿ø º´¸®°úÇб³½Ç
¹Ú¼ºÈ£ ( Park Seong-Hoe ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
±èÇѼº ( Kim Han-Seung ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ÀÏ»ê¹éº´¿ø º´¸®°ú
±è¾îÁø ( Kim Eo-Jin ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ °­ºÏ»ï¼ºº´¿ø º´¸®°úÇб³½Ç

Abstract


Background: Medullary thyroid carcinoma (MTC) that originates from C cells comprises about 10% of all the malignant thyroid tumors. Activating mutations of the RET proto-oncogene have been found to be involved in the anti-apoptotic pathway of MTC that harbors the RET mutation. We investigated the correlation between the clinicopathologic parameters and the expressions of survivin, a novel anti-apoptotic molecule, and the other apoptosis-related proteins, and the known prognostic markers.

Methods: Immunohistochemical staining was performed using antibodies for survivin, Fas, Fas ligand (FasL), bcl-2, calcitonin, CEA and cyclin A in 19 case of MTC; 10 sporadic MTCs, eight multiple endocrine neoplasia (MEN) type 2A MTCs and one
familial MTC (FMTC).

Results: Survivin protein expression was found in five cases (26%) and this was correlated with the presence of angiolymphatic tumor emboli (p=0.019). FasL was expressed in 14 cases (74%) and it had correlation with the presence of lymph node metastases (p=0.029). The cyclin A-labeling indices were correlated with local invasiveness (p=0.001).

Conclusions: Survivin and FasL might be involved in the lymphatic tumor spread of MTC.

Å°¿öµå

Survivin protein;Thyroid gland;Carcinoma;medullary

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS